Ironwood And Forest To Present Linaclotide Phase 3 Chronic Constipation Data
We recommend: without prescription aciphex, without prescription acomplia, without prescription amitriptyline
Also Included In: Clinical Trials / Drug Trials ; GastroIntestinal / Gastroenterology
netmail to a protagonist pressman favorable sight / spell opinions
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) now proclaimed they leave be presenting Phase 3 inveterate deadening clinical run results for linaclotide, an investigational guanylate cyclase type-C (GC-C) protagonist for the intervention of fractious gut syndrome with stultification (IBS-C) and continuing stultification (slipperwort010 Digestive Disease Week (DDW) one-year encounter organism held in New Orleans from May 1 done May 5, 2010. Ironwood and Forest released the top-line results from the CC trials recent conclusion year and anticipate to sustain information from the Phase 3 IBS-C trials in the irregular one-half of 2010.
The linaclotide CC information leave be reported in two unwritten presentations and one post-horse introduction. The scheduled multiplication and titles of the presentations are:
- Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients with Chronic Constipation: Results from Two Randomized, Double-blind, Placebo-controlled Phase 3 Trials , an unwritten demonstration by Anthony Lembo, M.D. on Monday, May 3 at 8:50 a.m. (CDT)
- Results from the Randomized Withdrawal Period of a Phase 3 Clinical Trial of Linaclotide in Chronic Constipation , a card of preeminence presented by Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Tuesday, May 4 at 12:00 p.m. - 2:00 p.m. (CDT)
- Effect of Linaclotide on Quality of Life in Adults with Chronic Constipation: Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials , a late-breaking, grand viva presentment by Robyn Carson, M.P.H. on Tuesday, May 4 at 4:45 p.m. (CDT)
In add-on, Ironwood and Forest bequeath salute qualitative search on symptoms of inveterate irregularity nearly crucial to patients in a card sitting on May 3 at DDW:
-Assessing Treatment Response in Chronic Constipation Clinical Trials: Concepts Elicited Through Qualitative Interviews With Patients, a bill introduction presented by Sheri Fehnel, Ph.D. on Monday, May 3 from 12:00 p.m. - 2:00 p.m. (CDT)
Linaclotide, an investigational dose, is an protagonist of guanylate cyclase type-C (GC-C), a receptor institute on epithelial cells liner the gut. Activation of GC-C leads to increases in intracellular and extracellular cyclical deoxyguanosine monophosphate (cGMP). In fauna models, extracellular cGMP inhibited afferent boldness release and positively moved markers of ab botheration, piece intracellular cGMP led to activating of anion channels which aroused anion and smooth division into the bowel, leadership to accelerated enteral transportation. Linaclotide is an orally delivered peptide that acts topically in the gut with no perceptible systemic picture at remedy doses and is intended for once-daily governing. Linaclotide is in Phase 3 clinical exploitation for the intervention of IBS-C and CC. In a Phase 2b cogitation in patients with IBS-C, linaclotide statistically importantly decreased ab infliction, ab uncomfortableness, rigorousness of twisting, and bloating, and increased discharge self-generated gut cause frequence, passim the 12-week intervention flow versus placebo. In two Phase 3 trials in patients with CC, statistical meaning versus placebo was achieved for the elemental endpoint-increasing over self-generated intestine movements-and all junior-grade endpoints, which included measures of twisting rigour, crapper rigor, bloating, and ab soreness. In Phase 2 IBS-C and Phase 3 CC trials, diarrhoea was the near commons contrary upshot, occurring at an incidence ‘tween 12 percentage and 20 percentage for linaclotide-treated patients (at the 133 to 266 mcg acid orbit) and ‘tween 1 pct and 7 pct for patients receiving placebo. Diarrhea was the nigh commons movement for discontinuance, although almost events of diarrhoea were reported as meek to tame. Data from the Phase 3 IBS-C trials are expected in the irregular one-half of 2010. An issued makeup of affair evident for linaclotide provides security to 2025. In September 2007, Ironwood and Forest entered into a 50/50 collaborationism to co-develop and co-promote linaclotide in the United States. Ironwood has out-licensed linaclotide to Almirall for European growth and commercialisation, and to Astellas Pharma for exploitation and commercialisation in Japan and over-the-counter Asian countries.
As many as 34 meg Americans hurt from symptoms associated with CC and 8.5 meg patients get sought-after intervention. Patients with CC ofttimes know grueling and chunky stools, torture during laxation, a sense of uncomplete voidance, and fewer than deuce-ace gut movements per hebdomad, as wellspring as soreness and bloating. This stipulation importantly affects patients’ timbre of aliveness by impairing their power to sour and enter in distinctive day-to-day activities. Half of patients are not quenched with presently usable treatments.
About Irritable Bowel Syndrome with Constipation (IBS-C)
IBS-C is a inveterate operable gi disorderliness characterized by ab bother, soreness, and bloating associated with adapted gut habits, and as many as 11 zillion citizenry in the U.S. sustain from it. There are presently few usable therapies to address this disarray and thither is a highschool rank of dissatisfaction with uncommitted therapies. Patients distress from IBS-C can be unnatural physically, psychologically, socially, and economically.
DDW is the largest outside gather of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gi or. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes spot May 1-5, 2010, at the Ernest N. Morial Convention Center, New Orleans. The merging showcases around 5,000 abstracts and hundreds of lectures on the up-to-the-minute advances in GI inquiry, medication and engineering. For more data, chit-chat http://www.ddw.org .
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutic party consecrate to the art and skill of gravid drugmaking. Linaclotide, Ironwood’s GC-C protagonist, is beingness evaluated in a substantiative Phase 3 broadcast for the discussion of peevish intestine syndrome with deadening (IBS-C) and continuing stultification. Ironwood too has a ontogeny grapevine of extra dose candidates in sooner stages of evolution. Ironwood is situated in Cambridge, Mass. To acquire more some Ironwood Pharmaceuticals, sojourn http://www.ironwoodpharma.com .
Forest Laboratories, Inc.
Any checkup entropy promulgated on this site is not intended as a backup for informed checkup advice and you should not proceeds any fulfil ahead consulting with a wellness maintenance master. For more data, delight understand our damage and weather .
For any corrections of actual data, or to tangency the editors delight use our feedback cast .
Please place any aesculapian tidings or wellness intelligence wardrobe releases to:
Personalized Homepage Weekly Newsletters Daily News Alerts
What Is…
Hemowarmness Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Parkinson’s Disease Stem Cells All ‘What Is…’ Articles
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us
Irritable-Bowel Syndrome Forum Discuss issues relating to irritable-bowel syndrome in our new assembly.
Severe IBS Symptoms Relieved By Non-Medical Treatment
Lexicon To Present Phase 2 Clinical Data For IBS Drug Candidate At Digestive Disease Week
Ironwood And Forest To Present Linaclotide Phase 3 Chronic Constipation Data
View more tidings…
Most Popular Articles For Irritable-Bowel Syndrome
These are the near translate articles from this intelligence family for the conclusion 6 months:
Sufferers Of Crohn’s Disease May Benefit From Vitamin D Supplements
A new discipline has launch that Vitamin D, promptly useable in supplements or cod liver-colored oil, can counterpunch the effects of Crohn’s disease. John White, an endocrinologist at the Research Institute of the McGill University Health…
Breakthrough On Causes Of Inflammatory Bowel Disease
New Tool To Accelerate Discovery Of Autoimmune Disease Mechanisms And Therapies
Distinct Demographic Profiles Between Crohn’s Disease And Ulcerative Colitis
Follow Our News On Twitter:
Get the up-to-the-minute intelligence for this family delivered square to your Twitter invoice. Simply detent the connection infra and take the ‘pursue’ pick.
Cancers of the GI organisation are among the almost preventable. Learn how simpleton changes in dieting can avail livelihood your digestive organisation hefty and maybe forbid colon cancer…
When you are an esurient smuggler, irregularity, bloating and ab botheration can strangle your tread. Listen to one soul key how she fought off overplus and ultimately went to see a bushel…
View more videos…
Today besellers: without prescription citalopram, without prescription crestor, without prescription cytotec
